Nevirapine Medical Valley (Nevirapine)

Nevirapine binds to a non‑nucleoside site on the HIV‑1 reverse transcriptase enzyme, causing a conformational change that blocks the enzyme’s ability to transcribe viral RNA into DNA. This inhibition stops viral replication and contributes to a reduction in plasma HIV levels.

The specific dose and dosing schedule are determined by the prescribing clinician based on the patient’s clinical status, weight, and other medications. Nevirapine is typically initiated with a lead‑in period to reduce the risk of rash and liver toxicity, but exact amounts must follow the prescriber’s order.

Nevirapine is classified as pregnancy category unknown. It may be used during pregnancy only when the potential benefits justify the potential risks to the fetus. Breastfeeding while on nevirapine is generally discouraged because the drug is excreted in breast milk; clinicians should evaluate each case individually.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain needs), and required import documentation.

Nevirapine and efavirenz belong to the same drug class but differ in pharmacokinetic profiles and side‑effect spectra. Nevirapine is often chosen for patients who cannot tolerate efavirenz’s central nervous system effects, while efavirenz may be preferred when a higher barrier to resistance is needed. Both require careful monitoring for liver toxicity and skin reactions.

Nevirapine Medical Valley tablets should be stored at ambient temperature, preferably below 25 °C, in the original blister or bottle to protect from moisture. Keep the product out of direct sunlight and away from excessive heat. No refrigeration is required.

The medication is taken orally, usually with food to lessen gastrointestinal upset. Tablets should be swallowed whole with a full glass of water. The exact timing and whether a lead‑in dose is required are determined by the prescribing physician.

The most critical adverse events include severe skin reactions such as Stevens‑Johnson syndrome or toxic epidermal necrolysis, and serious hepatotoxicity that can lead to liver failure. Early recognition of rash or jaundice and immediate discontinuation are essential to mitigate these risks.

Nevirapine should be avoided in patients with a known hypersensitivity to the drug, those with pre‑existing moderate to severe liver disease, and individuals who have previously experienced severe rash or hepatic reactions to nevirapine. Caution is also advised in pregnant women and patients on interacting medications.